The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.

Diane M Harper,Pekka Nieminen,Gilbert Donders,Mark H Einstein,Francisco Garcia,Warner K Huh,Mark H Stoler,Katerina Glavini,Gemma Attley,Jean-Marc Limacher,Berangere Bastien,Elizabeth Calleja

Gynecologic Oncology（2019）

引用 42|浏览17

暂无评分

摘要

•Tipapkinogen sovacivec completely resolves CIN 3 lesions significantly more frequently than placebo.•Tipapkinogen sovacivec completely clears HPV16 viral DNA associated with CIN 2/3 significantly more often than placebo.•Tipapkinogen sovacivec has significantly greater complete resolution rates of CIN 2/3 regardless of HR HPV type.•Tipapkinogen sovacivec offers 36% complete resolution or partial response of CIN2/3 associated with all HR HPV types.

查看译文

关键词

CIN 2/3,Immunotherapy,HPV,Cervical cancer,Therapeutic vaccine,Women

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.